Syntara shows encouraging first signals it can impact the path to Parkinson's
Syntara (ASX:SNT) has reported encouraging interim results from its Phase 2 study of SNT-4728, providing the first clinical evidence that the company’s novel anti-inflammatory therapy may be targeting a key biological process linked to the development of Parkinson’...
Market Cap $7.341B
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Last update - 16.33pm 06/07/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | $5.56 | Day High | $5.58 | Day Low | $5.39 | |||
| Daily Volume | 3213538 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | $5.41 | 7004 | 0 | $5.45 | 22924 | |
Directors & Senior Management
| Mr. Ang Li | Non-Executive Director |
| Mr. Brendan Fitzpatrick | General Manager of Investor Relations |
| Mr. David Bennett | Executive General Manager of Operations |
| Ms. Debra Anne Bakker | Independent Non-Executive Director |
| Mr. Frank Fulham | Chief Sustainability, Technology, Innovation & Development Officer |
| Mr. Gang Ru | Non-Executive Chairman |
| Mr. Gregory James Fletcher | Independent Co-Vice Chairman |
| Mr. Jiuhong Wang | Non-Executive Director |
| Ms. Ling Zhang | Company Secretary & Chief Legal, Compliance and Corporate Affairs Officer |
| Mr. Mark Salem | Executive General Manager of Marketing |
| Mr. Ning Su | Chief Financial Officer |
| Mr. Ning Yue | Executive Co-Vice Chairman |
| Mr. Peter Andrew Smith | Independent Non-Executive Director |
| Mr. Sharif Burra | Chief Executive Officer |
| Mr. Xiaolong Huang | Non-Executive Director |
| Mr. Zhiguo Zhao | Non-Executive Director |
Data source: ADVFN
